Weight Loss for Prediabetes: Diet, NHS Help

Weight loss for prediabetes is one of the most effective ways to prevent the condition from progressing to type 2 diabetes. Prediabetes, known clinically in the UK as non-diabetic hyperglycaemia (NDH), affects millions of people in England, many of whom are unaware of their diagnosis. The encouraging reality is that prediabetes is frequently reversible, and even modest, sustained weight loss can meaningfully improve insulin sensitivity, lower HbA1c, and restore blood glucose to a normal range. This article explains how much weight loss helps, which dietary and lifestyle approaches have the strongest evidence, and what NHS and pharmacological support is available.

What is prediabetes and why does weight matter?

Prediabetes is a reversible condition where blood glucose is above normal but below the diabetic threshold; excess visceral fat drives insulin resistance, making weight loss the most evidence-supported intervention.

Prediabetes, also referred to in NHS and clinical settings as non-diabetic hyperglycaemia (NDH), is a condition in which blood glucose levels are higher than normal but not yet high enough to meet the diagnostic threshold for type 2 diabetes. Excess body weight is one of the most significant modifiable risk factors driving its progression. The condition is typically identified through an HbA1c reading of 42 to 47 mmol/mol, or a fasting plasma glucose of 6.1 to 6.9 mmol/L, depending on the test used and local pathway. NHS England estimates that millions of people in England are living with prediabetes or NDH, many of whom are unaware of their status.

Excess adipose tissue, particularly visceral fat stored around the abdomen, contributes directly to insulin resistance. When cells become less responsive to insulin, the pancreas compensates by producing more, and over time this mechanism can fail, allowing blood glucose to rise further. Carrying excess weight also promotes low-grade systemic inflammation, which compounds metabolic dysfunction.

The encouraging news is that prediabetes is not inevitable in its progression. Unlike established type 2 diabetes, NDH is frequently reversible, and weight loss is the single most evidence-supported intervention for reducing that risk. Even modest reductions in body weight can meaningfully improve insulin sensitivity, lower HbA1c, and restore blood glucose to a normal range. Understanding the relationship between weight and glucose regulation is therefore the starting point for anyone who has received a prediabetes or NDH diagnosis.

How much weight do you need to lose to reverse prediabetes?

Losing 5 to 10 per cent of body weight is associated with clinically meaningful HbA1c improvements and can reduce the risk of progressing to type 2 diabetes by around 50 per cent or more.

Losing 5 to 10 per cent of body weight is associated with clinically meaningful improvements in blood glucose control in people with prediabetes, and greater losses are linked to higher rates of remission. Evidence from the landmark US Diabetes Prevention Program (DPP) and the Finnish Diabetes Prevention Study (DPS), as well as NHS Diabetes Prevention Programme (NHS DPP) evaluation data, consistently shows that this level of weight reduction can reduce the risk of progressing to type 2 diabetes by around 50 per cent or more over several years.^[5]

For someone weighing 100 kg, a 5 per cent reduction equates to 5 kg, which is an achievable target for most people through sustained dietary and lifestyle changes. Losses of 10 per cent or more are associated with even greater benefits, including improvements in blood pressure, lipid profiles, and markers of cardiovascular risk, all of which are commonly elevated in people with prediabetes.

It is important to note that the rate of weight loss matters less than its sustainability. Rapid weight loss followed by regain offers limited long-term metabolic benefit. Gradual, sustained reduction, typically 0.5 to 1 kg per week, achieved through a calorie deficit and increased physical activity, is more likely to produce durable improvements in HbA1c. The term 'reversal' should be understood as a return to normoglycaemia rather than a guaranteed permanent cure; ongoing monitoring remains important. Your GP or diabetes prevention team can help you set a realistic and personalised weight loss target based on your current BMI, HbA1c level, and overall health.

Which diet and lifestyle changes work best for prediabetes in the UK?

A reduced-calorie diet combined with at least 150 minutes of moderate aerobic activity per week is the most effective strategy, with low-calorie, Mediterranean-style, and low-carbohydrate diets all showing strong evidence.

A reduced-calorie diet combined with regular physical activity remains the most effective lifestyle strategy for weight loss and blood glucose improvement in prediabetes, and NICE public health guidance on preventing type 2 diabetes in people at high risk supports this as the foundation of management. No single dietary pattern has been shown to be universally superior, but several approaches have strong evidence behind them.

Dietary approaches with good evidence include:

• Low-calorie or total diet replacement programmes (typically 800 to 1,200 kcal per day), which can produce rapid initial weight loss and significant HbA1c reductions; the DiRECT trial demonstrated substantial remission rates with this approach. Very low-calorie diets should be undertaken with medical supervision to ensure nutritional adequacy and appropriate monitoring.

• Mediterranean-style eating, rich in vegetables, legumes, wholegrains, fish, and olive oil, which improves insulin sensitivity and cardiovascular risk markers

• Low-carbohydrate diets, which reduce postprandial glucose spikes and can lower HbA1c, though long-term adherence varies; Diabetes UK has published evidence-based guidance on this approach

• Portion-controlled, balanced eating based on the NHS Eatwell Guide, which is practical and sustainable for many people

Physical activity is equally important. The UK Chief Medical Officers' physical activity guidelines recommend at least 150 minutes of moderate-intensity aerobic activity per week, such as brisk walking, cycling, or swimming, alongside muscle-strengthening activities on two or more days.^[6][7] Exercise improves insulin sensitivity independently of weight loss, meaning even people who do not lose significant weight can reduce their diabetes risk through regular movement.

Behavioural support, including goal-setting, self-monitoring, and structured education, substantially improves adherence to lifestyle changes. The NHS DPP provides this support free of charge to eligible individuals in England. Reducing alcohol intake and improving sleep quality are additional factors that influence glucose regulation and should not be overlooked.

Can weight loss medication help if diet and exercise are not enough?

MHRA-authorised options including semaglutide (Wegovy), tirzepatide (Mounjaro), and orforglipron (Foundayo) may be appropriate when lifestyle changes are insufficient, subject to NICE eligibility criteria and prescriber assessment.

Weight loss medication may be appropriate for people with prediabetes who have not achieved sufficient weight loss through diet and lifestyle changes alone, particularly where BMI meets the threshold for pharmacological treatment. NICE technology appraisals have recommended several medicines for chronic weight management, each with its own specific eligibility criteria, including BMI thresholds, required comorbidities, specialist service requirements, and stopping rules. NHS access to these medicines depends on local commissioning decisions by Integrated Care Boards (ICBs) and on referral through appropriate specialist pathways.

Currently MHRA-authorised options for weight management in the UK include:

• Orlistat, which reduces dietary fat absorption and is available on NHS prescription or over the counter^[16]

• Semaglutide (Wegovy), a GLP-1 receptor agonist given as a weekly subcutaneous injection, with authorised strengths including doses above 2.4 mg, and, following MHRA authorisation in June 2026, an oral formulation (Wegovy 25 mg tablets) also available

• Tirzepatide (Mounjaro), a dual GIP and GLP-1 receptor agonist, MHRA-authorised both for type 2 diabetes and for chronic weight management^[1][8]

• Liraglutide (Saxenda), a daily injectable GLP-1 receptor agonist

• Orforglipron (Foundayo), an oral GLP-1 receptor agonist authorised by the MHRA for chronic weight management^[11][12]

GLP-1 and dual agonist medicines work by slowing gastric emptying, reducing appetite, and improving insulin secretion in a glucose-dependent manner.^[13][14] These mechanisms are particularly relevant in prediabetes, where improving insulin sensitivity and reducing caloric intake together address the underlying pathology.

All weight loss medicines should be used alongside dietary and lifestyle changes, not as a replacement for them. These medicines are not suitable for use during pregnancy or breastfeeding, and individual suitability, potential interactions, and monitoring requirements must be assessed by a qualified prescriber. Patients should read the patient information leaflet (PIL) supplied with their medicine. Suspected side effects should be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where a medicine may be considered if it is clinically appropriate. Eligibility, suitability, and local commissioning decisions vary, so a conversation with your GP or a qualified prescriber is the appropriate starting point.

What does the NHS offer to support weight loss in prediabetes?

The NHS Diabetes Prevention Programme (Healthier You) provides up to nine months of free structured support for people with an HbA1c of 42 to 47 mmol/mol, with referral typically made by a GP.

The NHS Diabetes Prevention Programme (NHS DPP), known as Healthier You, is the primary structured intervention available in England for people identified with non-diabetic hyperglycaemia (prediabetes), and referral is typically made by a GP or practice nurse following a blood test. The programme offers up to nine months of group or digital support, covering healthy eating, physical activity, and behaviour change techniques. NHS England evaluation data shows that participants who complete the programme achieve meaningful reductions in weight and HbA1c.^[20][21]

Eligibility for the NHS DPP is based on an HbA1c of 42 to 47 mmol/mol or a fasting plasma glucose of 6.1 to 6.9 mmol/L, recorded within the past 12 months. Referrals can be made by healthcare professionals, and a digital version of the programme is available for those who prefer remote access or have difficulty attending in person. Specific eligibility criteria and referral routes are set out in the NHS DPP service specification published by NHS England, and it is worth confirming current requirements with your GP or practice.

Beyond the DPP, NHS services that may support weight management in prediabetes include:

• GP-led weight management advice and referral to local tier 2 or tier 3 weight management services

• NHS Digital Weight Management Programme, a behavioural support service available to eligible adults; specific inclusion criteria and referral pathways apply

• Specialist weight management clinics for people with complex needs or significant obesity

Availability of these services varies by Integrated Care Board (ICB) area, and local commissioning decisions determine which interventions are funded. If you have been told you have prediabetes or NDH, asking your GP about NHS DPP referral is a practical and evidence-based first step.

How long does it take to see results and reduce your diabetes risk?

Blood glucose improvements can begin within weeks of sustained lifestyle change, with HbA1c rechecked at six to twelve months; a result below 42 mmol/mol indicates successful return to the normal range.

Meaningful improvements in blood glucose can begin within weeks of sustained dietary change and increased physical activity, though the timeline varies considerably depending on the degree of weight loss achieved, baseline HbA1c, and individual metabolic factors. Some people see HbA1c return to the normal range within a few months of consistent lifestyle change, particularly when weight loss of 5 per cent or more is achieved, though individual responses differ and this is not guaranteed.

Longer-term risk reduction depends on sustaining those changes. Data from the Diabetes Prevention Program, the Finnish DPS, and NHS DPP follow-up studies indicate that the protective effect of weight loss on diabetes risk persists for several years in people who maintain their lower weight. Conversely, weight regain is associated with a return of elevated glucose levels, which underlines the importance of ongoing support and monitoring.

Your GP or diabetes prevention team will typically recheck your HbA1c at six to twelve months after a prediabetes diagnosis to assess progress, in line with UK follow-up guidance for NDH. Key signs that your intervention is working include:

• HbA1c falling below 42 mmol/mol, indicating a return to the normal range

• Sustained weight loss of 5 per cent or more from baseline

• Improved fasting glucose on repeat testing

• Better energy levels, blood pressure, and lipid results

If your HbA1c has not improved after six months of lifestyle change, or if it rises towards the diabetic range (48 mmol/mol or above), contact your GP to discuss whether additional support or pharmacological treatment is appropriate. Regular monitoring is not a sign of failure; it is the mechanism by which your care team can adjust your plan and keep your risk as low as possible.

Scientific References

1. Mounjaro KwikPen 10mg solution for injection in pre-filled pen – Summary of Product Characteristics.
2. Type 2 diabetes: prevention in people at high risk (PH38) – Recommendations.
3. Mounjaro – European Public Assessment Report.
4. Type 2 diabetes – Treatment summaries (BNF/NICE).
5. The Finnish Diabetes Prevention Study (DPS).
6. Physical activity guidelines: UK Chief Medical Officers' report.
7. Physical activity guidelines for adults aged 19 to 64.
8. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss.
9. Tirzepatide – Drug monograph (BNF/NICE).
10. Tirzepatide – NHS medicines information.
11. UK first in Europe to authorise orforglipron for weight management and type 2 diabetes.
12. New oral GLP-1 medicine for weight management and type 2 diabetes (Foundayo/orforglipron).
13. The Clinical Application of GLP-1RAs and GLP-1/GIP Dual Receptor Agonists Based on Pharmacological Mechanisms: A Review. Drug Design, Development and Therapy..
14. Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation. The American Journal of Medicine..
15. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update. Diabetes, Obesity & Metabolism..
16. Orlistat – NHS medicines information.
17. Liraglutide – Drug monograph (BNF/NICE).
18. GLP-1 medicines for weight loss and diabetes: what you need to know.
19. First GLP-1 tablet for weight loss approved in the UK (Wegovy 25 mg tablets – semaglutide).
20. Early Outcomes From the English National Health Service Diabetes Prevention Programme. Diabetes Care..
21. 'Finishing the race' – a cohort study of weight and blood glucose change among the first 36,000 patients in a large-scale diabetes prevention programme. International Journal of Behavioral Nutrition and Physical Activity..
22. Cost-effectiveness of the diabetes remission clinical trial (DiRECT)/Counterweight-Plus weight management programme, based on 5-year follow-up. Diabetic Medicine..
23. An eHealth-Delivered Total Diet Replacement Intervention for Type 2 Diabetes Remission: Single-Arm Pilot Study. JMIR Diabetes..
24. Blood glucose management – Type 2 diabetes in adults (NG28).

Frequently Asked Questions